Print Page     Close Window     

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
08/07/17
Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
Expects top-line data from LEAP 1 CABP Phase 3 trial in September 2017 and from LEAP 2 CABP Phase 3 trial in the first quarter 2018 DUBLIN, Ireland, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its ... 
08/02/17
Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Gary Sender, Chief Financial Officer of Nabriva Therapeutics plc, will provide a company overview and business update at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16... 
07/11/17
Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Francesco Maria Lav... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.